Eli Lilly (Lly) win Q4 2024

Eli Lilly reported mixed results in the fourth quarter on Thursday when the turnover of his blockbuster weight loss Zepbound and diabetes Drug Mounjaro rose, but saw lower prices.

The figures agreed with the preliminary results that Eli Lilly shared in January that disappointed investors. Eli Lilly had reduced his intake of 2024 because the demand for weight loss and diabetes medication would not meet its high expectations.

Wall Street estimated the company’s quarterly profit, but sales were only brief.

The pharmaceutical giant also gave the profit line of $ 22.05 to $ 23.55 per share, which awaited the analyst. Eli Lilly confirmed his sales advice of 58 billion US dollars up to $ 61 billion.

The following reported Eli Lilly in the fourth quarter compared to the expectations of Wall Street, based on a survey of LSEG analysts:

• Result per share: $ 5.32 adapted compared to USD 4.95
• Revenue: 13.53 billion US dollars expected compared to $ 13.57 billion

The company generated sales of $ 13.53 billion in the fourth quarter, which rose to an increase of 45% compared to the same period in the previous year.

In the fourth quarter, the pharmaceutical booked a net income of 4.41 billion US dollars or $ 4.88 per share. This is compared to a profit of 2.19 billion US dollars or $ 2.42 per share in the previous year.

Without unique elements associated with the value of intangible assets and other adjustments, Eli Lilly achieved the result of $ 5.32 per share for the fourth quarter of 2024.

This story develops. Please check for updates.